Royalty Pharma Statistics

Total Valuation

Royalty Pharma has a market cap or net worth of $21.26 billion. The enterprise value is $28.64 billion.

Market Cap	21.26B
Enterprise Value	28.64B

Important Dates

The last earnings date was Wednesday, August 6, 2025, before market open.

Earnings Date	Aug 6, 2025
Ex-Dividend Date	Aug 15, 2025

Share Statistics

Royalty Pharma has 583.17 million shares outstanding. The number of shares has decreased by -2.95% in one year.

Current Share Class	432.29M
Shares Outstanding	583.17M
Shares Change (YoY)	-2.95%
Shares Change (QoQ)	-2.73%
Owned by Insiders (%)	11.56%
Owned by Institutions (%)	76.70%
Float	380.08M

Valuation Ratios

The trailing PE ratio is 15.68 and the forward PE ratio is 7.22. Royalty Pharma's PEG ratio is 0.65.

PE Ratio	15.68
Forward PE	7.22
PS Ratio	6.93
Forward PS	8.83
PB Ratio	2.48
P/TBV Ratio	3.92
P/FCF Ratio	n/a
P/OCF Ratio	8.84
PEG Ratio	0.65

Financial Ratio History

Enterprise Valuation

EV / Earnings	28.06
EV / Sales	12.42
EV / EBITDA	n/a
EV / EBIT	15.32
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.84.

Current Ratio	1.26
Quick Ratio	1.26
Debt / Equity	0.84
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	7.02

Financial Efficiency

Return on equity (ROE) is 17.29% and return on invested capital (ROIC) is 6.70%.

Return on Equity (ROE)	17.29%
Return on Assets (ROA)	6.49%
Return on Invested Capital (ROIC)	6.70%
Return on Capital Employed (ROCE)	10.92%
Revenue Per Employee	$23.29M
Profits Per Employee	$10.31M
Employee Count	99
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +37.90% in the last 52 weeks. The beta is 0.54, so Royalty Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	+37.90%
50-Day Moving Average	35.77
200-Day Moving Average	31.55
Relative Strength Index (RSI)	50.17
Average Volume (20 Days)	2,867,987

Short Selling Information

The latest short interest is 15.18 million, so 2.60% of the outstanding shares have been sold short.

Short Interest	15.18M
Short Previous Month	16.73M
Short % of Shares Out	2.60%
Short % of Float	3.99%
Short Ratio (days to cover)	5.25

Income Statement

In the last 12 months, Royalty Pharma had revenue of $2.31 billion and earned $1.02 billion in profits. Earnings per share was $2.32.

Revenue	2.31B
Gross Profit	2.70B
Operating Income	1.87B
Pretax Income	673.24M
Net Income	1.02B
EBITDA	n/a
EBIT	1.87B
Earnings Per Share (EPS)	$2.32

Full Income Statement

Balance Sheet

The company has $645.11 million in cash and $8.02 billion in debt, giving a net cash position of -$7.38 billion or -$12.65 per share.

Cash & Cash Equivalents	645.11M
Total Debt	8.02B
Net Cash	-7.38B
Net Cash Per Share	-$12.65
Equity (Book Value)	9.50B
Book Value Per Share	14.68
Working Capital	313.72M

Full Balance Sheet

Cash Flow

Operating Cash Flow	2.41B
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 117.12%, with operating and profit margins of 81.09% and 44.28%.

Gross Margin	117.12%
Operating Margin	81.09%
Pretax Margin	72.22%
Profit Margin	44.28%
EBITDA Margin	n/a
EBIT Margin	81.09%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of $0.88, which amounts to a dividend yield of 2.45%.

Dividend Per Share	$0.88
Dividend Yield	2.45%
Dividend Growth (YoY)	4.82%
Years of Dividend Growth	5
Payout Ratio	37.43%
Buyback Yield	2.95%
Shareholder Yield	5.36%
Earnings Yield	4.80%
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for Royalty Pharma is $46.75, which is 28.22% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$46.75
Price Target Difference	28.22%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	15.66%
EPS Growth Forecast (5Y)	35.24%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Royalty Pharma has an Altman Z-Score of 1.54 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.54
Piotroski F-Score	6